A Phase II trial of paclitaxel in refractory germ cell tumors

Cancer

Volumn 82, Issue 7, 1998, Pages 1381-1386

  Sandler, Alan B ^a,b   Cristou, Antonios ^a   Fox, Susan ^a   Williams, Stephen D ^a   Nichols, Craig R ^a   Turns, Martine ^a   Roth, Bruce J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Indiana Cancer Pavilion   (United States)

Author keywords

Chemotherapy; Germ cell tumor; Paclitaxel; Testes cancer

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; GERM CELL TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TESTIS CANCER; TREATMENT FAILURE; TREATMENT INDICATION;

ADOLESCENT; ADULT; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PACLITAXEL; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 0032055188     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980401)82:7<1381::AID-CNCR23>3.0.CO;2-1     Document Type: Article

References (24)

1. Einhorn LH, Williams SD, Loehrer PJ, Birch R, Drasga R. Omura G, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study group protocol. J Clin Oncol 1989;7:387-91.
2. Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993;11:598-606.
3. Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southerwestern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991;9:1163-72.
4. Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC. A randomized trial of standard chemotherapy versus a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ cell tumors. J Clin Oncol 1988;6:1031-40.
5. Motzer RJ, Mazumbar M, Gulati SC, Bajorin DF, Lyn P, Vlamis V, et al. Phase II trial of high dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993;85:1828-35.
6. Loehrer PJ, Lauer R, Roth BJ, Williams SD, Kalacinski LA, Einhorn LH. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastin or etoposide. Ann Int Med 1986;109:540-6.
7. Hainsworth J, Williams SD, Einhorn LH, Birch R, Greco F. Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial. J Clin Oncol 1985;3:666-71.
8. Motzer RJ, Cooper K, Geller NL, Bajorin DF, Dmitrovsky E, Hen H, et al. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 1990;66:2476-81.
9. Broun ER, Nichols CR, Kneebone P, Williams SD, Loehrer PJ, Einhorn LH, et al. Long term outcome of patients with relapsed germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Int Med 1992;117:124-8.
10. Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ, et al. Surgical salvage of chemotherapy refractory germ cell tumors. J Clin Oncol 1993;11:324-9.
11. Saxman SB, Nichols CR, Einhorn LH. Salvage chemotherapy in patients with extagonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol 1994;12:1390-3.
12. Blanke C, Loehrer PJ, Einhonr LH, Nichols C. A phase II study of VP-16 plus ifosfamide plus cisplatin plus vinblastine plus bleomycin (VIP/VB) with filgrastim for advanced stage testicular cancer. Proc Am Soc Clin Oncol 1994;13:234.
13. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;22:665-7.
14. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblasts cells. Proc Natl Acad Sci USA 1980; 77:1561-5.
15. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517-24.
16. Motzer RJ, Bajorin DF, Schwartz LH, Hutter HS, Bosl GJ, Scher HI, et al. Phase II trial of paclitaxel shows antitumor activity inpatients with previously treated germ cell tumors. J Clin Oncol 1994;12:2277-83.
17. Bokemeyer C, Beyer J, Metzer B, Ruther U, Harstrick A, Weißach L, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996;7:31-4.
18. Nasario A, Amato RJ, Hutchinson L, Bui C, Ellerhorst J, Logothetis C. Paclitaxel in extensively pretreated nonseminomatous germ cell tumors. Urol Oncol 1995;1:184-7.
19. Motzer RJ, Bajorin DF, Bosi GJ, Reich L, Tong W, Green GA. Paclitaxel containing first-line salvage therapy selected by risk for patients with germ cell tumors. Proc Am Soc Clin Oncol 1997;16:322a.
20. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol 1995;13:1170-6.
21. Arbuck SG, Canetta R, Onetto N, Christian MC. Current dosage and schedule issues in the development of Paclitaxel (TAXOL). Semin Oncol 1993;20:(Suppl 3)31-39.
22. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg MEL, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
23. Rowinsky EK, Mackey MK, Goodman SN. Meta analysis of paclitaxel dose-response and dose-intensity in recurrent or refractory ovarian cancer. Proc Am Soc Oncol 1996;15:284.
24. Bonomi P, Kim K, Chang A, Johnson D. Phase III trial comparing etoposide-cisplatin versus taxol with cisplatin-G-CSF versus taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol 1996;15:382.